During the past decades, intensive efforts have been made to overcome the acquired drug resistance leading to the identification of complex factors/pathways contributing to tamoxifen resistance including the growth factor receptor networks (EGFR/HER2), the NF-κB pathway as well as the contribution of cancer stem cells [1, 4, 5]. The gene discussed is EGFR; the disease is cancer.